Avecho Biotechnology Ltd - Asset Resilience Ratio
Avecho Biotechnology Ltd (AVE) has an Asset Resilience Ratio of 82.51% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Avecho Biotechnology Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1993–2024)
This chart shows how Avecho Biotechnology Ltd's Asset Resilience Ratio has changed over time. See net assets of Avecho Biotechnology Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Avecho Biotechnology Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AVE stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$5.93 Million | 82.51% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$5.93 Million | 82.51% |
Asset Resilience Insights
- Very High Liquidity: Avecho Biotechnology Ltd maintains exceptional liquid asset reserves at 82.51% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Avecho Biotechnology Ltd Industry Peers by Asset Resilience Ratio
Compare Avecho Biotechnology Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 1.39% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 3.87% |
Annual Asset Resilience Ratio for Avecho Biotechnology Ltd (1993–2024)
The table below shows the annual Asset Resilience Ratio data for Avecho Biotechnology Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 47.52% | AU$2.37 Million ≈ $1.68 Million |
AU$5.00 Million ≈ $3.54 Million |
+47.31pp |
| 2023-12-31 | 0.21% | AU$15.73K ≈ $11.13K |
AU$7.32 Million ≈ $5.18 Million |
-46.23pp |
| 2022-12-31 | 46.45% | AU$1.55 Million ≈ $1.10 Million |
AU$3.35 Million ≈ $2.37 Million |
-15.79pp |
| 2021-12-31 | 62.23% | AU$3.26 Million ≈ $2.31 Million |
AU$5.25 Million ≈ $3.71 Million |
+6.41pp |
| 2020-12-31 | 55.83% | AU$1.87 Million ≈ $1.33 Million |
AU$3.35 Million ≈ $2.37 Million |
-4.58pp |
| 2019-12-31 | 60.40% | AU$3.21 Million ≈ $2.27 Million |
AU$5.32 Million ≈ $3.76 Million |
+15.26pp |
| 2018-12-31 | 45.15% | AU$2.17 Million ≈ $1.53 Million |
AU$4.80 Million ≈ $3.40 Million |
+4.45pp |
| 2017-12-31 | 40.70% | AU$3.35 Million ≈ $2.37 Million |
AU$8.24 Million ≈ $5.83 Million |
+39.16pp |
| 2016-12-31 | 1.54% | AU$205.00K ≈ $145.05K |
AU$13.35 Million ≈ $9.45 Million |
+1.49pp |
| 2003-12-31 | 0.05% | AU$13.78K ≈ $9.75K |
AU$29.41 Million ≈ $20.81 Million |
+0.05pp |
| 2002-12-31 | 0.00% | AU$-429.00 ≈ $-303.54 |
AU$14.84 Million ≈ $10.50 Million |
-1.31pp |
| 2001-12-31 | 1.30% | AU$240.00K ≈ $169.82K |
AU$18.40 Million ≈ $13.02 Million |
-0.61pp |
| 2000-12-31 | 1.92% | AU$400.00K ≈ $283.03K |
AU$20.86 Million ≈ $14.76 Million |
+1.34pp |
| 1999-12-31 | 0.58% | AU$29.44K ≈ $20.83K |
AU$5.10 Million ≈ $3.61 Million |
+0.58pp |
| 1996-12-31 | 0.00% | AU$-499.00 ≈ $-353.07 |
AU$33.01 Million ≈ $23.36 Million |
-84.53pp |
| 1993-12-31 | 84.53% | AU$10.04 Million ≈ $7.10 Million |
AU$11.88 Million ≈ $8.40 Million |
-- |
About Avecho Biotechnology Ltd
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic f… Read more